Charmacy Pharmaceutical Co., Ltd. provided earnings guidance for the ended 31 December 2021. For the period, the group is expected to report a net profit attributable to the shareholders of the parent company of approximately RMB 21.00 million to RMB 25.00 million for the Year, representing a decrease of approximately 38% to 48% as compared with that of the year ended 31 December 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.7 HKD | -1.14% | -39.58% | -32.87% |
05-21 | Charmacy Pharmaceutical to Pay Final Dividend | MT |
04-01 | Charmacy Pharmaceutical 2023 Profit Declines on Lower Asset Disposal Gains | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.87% | 122M | |
-31.33% | 11.31B | |
+15.73% | 6.47B | |
-30.66% | 6.32B | |
-8.33% | 6.09B | |
+74.00% | 4.95B | |
-1.61% | 4.67B | |
-6.00% | 3.95B | |
-14.62% | 3.34B | |
-12.02% | 2.92B |
- Stock Market
- Equities
- 2289 Stock
- News Charmacy Pharmaceutical Co., Ltd.
- Charmacy Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Ended 31 December 2021